tetano
Editor, Senior Moderator
Tuberc Respir Dis (Seoul)
. 2021 Nov 30.
doi: 10.4046/trd.2021.0102. Online ahead of print.
Association between inhaled corticosteroid use and SARS-CoV-2 infection: A nationwide population-based study in South Korea
Sang Chul Lee[SUP] 1 2 [/SUP], Kang Ju Son[SUP] 3 4 [/SUP], Chang Hoon Han[SUP] 1 [/SUP], Ji Ye Jung[SUP] 5 [/SUP], Seon Cheol Park[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Inhaled corticosteroid (ICS) use may increase the risk of respiratory infection, but its influence on the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is not known. This study aimed to investigate the association between ICS use and the positivity of SARS-CoV-2 infection among the patients with chronic respiratory diseases.
Methods: The Ministry of Health and Welfare and Health Insurance Review and Assessment Service in Korea provided nationwide data of 44,968 individuals with chronic respiratory diseases tested for SARS-CoV-2 until May 15. The positivity of SARS-CoV-2 infection were retrospectively analysed according to the prescription, type, and dose of ICS taken one year before SARS-CoV-2 test.
Results: Among 44,968 individuals tested, 931 (2.1%) were positive for SARS-CoV-2. A total of 7,019 patients (15.6%) were prescribed ICS one year prior to being tested for SARS-CoV-2. Low, medium, and high doses of ICS were prescribed in 7.5%, 1.6%, and 6.5% of total cases, respectively. Among the types of ICS, budesonide, fluticasone, beclomethasone, and ciclesonide were prescribed in 3.7%, 8.9%, 2.3%, and 0.6% of total cases, respectively. The multivariate analysis showed no significant increase in infection with ICS use (OR, 0.84; 95% CI, 0.66-1.03). Moreover, there were no associations between the positivity of infection, and doses or types of ICS prescribed.
Conclusion: Prior ICS use did not increase the positivity for SARS-CoV-2 infection. Moreover, different doses or types of ICS did not affect the positivity.
Keywords: Inhaled corticosteroid; chronic respiratory diseases; risk; severe acute respiratory syndrome coronavirus 2.
. 2021 Nov 30.
doi: 10.4046/trd.2021.0102. Online ahead of print.
Association between inhaled corticosteroid use and SARS-CoV-2 infection: A nationwide population-based study in South Korea
Sang Chul Lee[SUP] 1 2 [/SUP], Kang Ju Son[SUP] 3 4 [/SUP], Chang Hoon Han[SUP] 1 [/SUP], Ji Ye Jung[SUP] 5 [/SUP], Seon Cheol Park[SUP] 1 [/SUP]
Affiliations
- PMID: 34844402
- DOI: 10.4046/trd.2021.0102
Abstract
Background: Inhaled corticosteroid (ICS) use may increase the risk of respiratory infection, but its influence on the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is not known. This study aimed to investigate the association between ICS use and the positivity of SARS-CoV-2 infection among the patients with chronic respiratory diseases.
Methods: The Ministry of Health and Welfare and Health Insurance Review and Assessment Service in Korea provided nationwide data of 44,968 individuals with chronic respiratory diseases tested for SARS-CoV-2 until May 15. The positivity of SARS-CoV-2 infection were retrospectively analysed according to the prescription, type, and dose of ICS taken one year before SARS-CoV-2 test.
Results: Among 44,968 individuals tested, 931 (2.1%) were positive for SARS-CoV-2. A total of 7,019 patients (15.6%) were prescribed ICS one year prior to being tested for SARS-CoV-2. Low, medium, and high doses of ICS were prescribed in 7.5%, 1.6%, and 6.5% of total cases, respectively. Among the types of ICS, budesonide, fluticasone, beclomethasone, and ciclesonide were prescribed in 3.7%, 8.9%, 2.3%, and 0.6% of total cases, respectively. The multivariate analysis showed no significant increase in infection with ICS use (OR, 0.84; 95% CI, 0.66-1.03). Moreover, there were no associations between the positivity of infection, and doses or types of ICS prescribed.
Conclusion: Prior ICS use did not increase the positivity for SARS-CoV-2 infection. Moreover, different doses or types of ICS did not affect the positivity.
Keywords: Inhaled corticosteroid; chronic respiratory diseases; risk; severe acute respiratory syndrome coronavirus 2.